Centessa Pharmaceuticals’ (CNTA) “Buy” Rating Reaffirmed at Guggenheim

Centessa Pharmaceuticals (NASDAQ:CNTA)‘s stock had its “buy” rating reissued by stock analysts at Guggenheim in a report released on Wednesday,Benzinga reports. They currently have a $28.00 target price on the stock. Guggenheim’s price target indicates a potential upside of 87.54% from the stock’s previous close.

Several other equities analysts also recently issued reports on the company. TD Cowen started coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $26.00.

Centessa Pharmaceuticals Trading Down 5.6 %

Centessa Pharmaceuticals stock traded down $0.88 during trading hours on Wednesday, hitting $14.93. The company had a trading volume of 155,097 shares, compared to its average volume of 527,967. The firm has a market cap of $1.97 billion, a P/E ratio of -9.71 and a beta of 1.54. The company has a 50-day moving average price of $16.51 and a two-hundred day moving average price of $16.43. Centessa Pharmaceuticals has a 1 year low of $7.75 and a 1 year high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.04. On average, sell-side analysts anticipate that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $15.29, for a total transaction of $91,740.00. Following the transaction, the general counsel now directly owns 118,265 shares in the company, valued at approximately $1,808,271.85. The trade was a 4.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $17.04, for a total transaction of $170,400.00. Following the completion of the sale, the insider now owns 183,266 shares of the company’s stock, valued at approximately $3,122,852.64. The trade was a 5.17 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 260,168 shares of company stock valued at $4,316,568 over the last ninety days. Corporate insiders own 11.59% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its holdings in Centessa Pharmaceuticals by 14.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company’s stock valued at $89,854,000 after purchasing an additional 685,371 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Centessa Pharmaceuticals by 22.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock worth $85,744,000 after purchasing an additional 924,027 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Centessa Pharmaceuticals by 279.2% during the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock worth $82,218,000 after buying an additional 3,614,623 shares during the period. Farallon Capital Management LLC grew its stake in shares of Centessa Pharmaceuticals by 24.3% in the fourth quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company’s stock valued at $58,603,000 after buying an additional 684,391 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its holdings in shares of Centessa Pharmaceuticals by 26.2% in the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company’s stock valued at $57,396,000 after buying an additional 710,936 shares during the period. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.